A Model of Ischemic Isolated Acute Liver Failure in Pigs: Standardizing Monitoring and TreatmentAl-Chalabi A.a · Matevossian E.b · Preiβel A.c · Perren A.d, g · Yang Z.a · Schuster T.e · Schreiber C.a · Schimmel P.a · Nairz E.a · Yan H.a · Geiger A.a · Kreymann B.f
Departments of aMedicine II and bSurgery, and cInstitute of Preclinical Studies, Klinikum rechts der Isar, dInstitute of Pathology, and eInstitute of Medical Statistics and Epidemiology, Technical University Munich, and fHepa Wash GmbH, Munich, Germany; gInstitute of Pathology, University of Bern, Bern, Switzerland
II Medizinische Klinik und Poliklinik, Klinikum rechts der Isar
DE–81675 Munich (Germany)
Tel. +49 89 4140 7288, Fax +49 89 4140 7301, E-Mail firstname.lastname@example.org
Do you have an account?
Background: Acute liver failure (ALF) models in pigs have been widely used for evaluating newly developed liver support systems. But hardly any guidelines are available for the surgical methods and the clinical management. Methods: The study validated several standard operating procedures describing in detail the surgical method and intensive care monitoring and treatment (control of potassium, glucose and bicarbonate levels, cardiovascular and intracranial pressure monitoring, etc.). ALF was induced in animals with a mean of 56 kg. Two surgical methods were compared: ligation of hepatic arteries with either end-to-side portacaval shunt (ESPS) and bile duct ligation or side-to-side portacaval shunt (SSPS) without bile duct ligation. Results: During total portal vein clamping, the animals in the ESPS group developed severe hypotension, splanchnic congestion and metabolic acidosis. One animal died after approximately 1.5 h. This model therefore represents a multiorgan failure model rather than an isolated ALF model. In the SSPS group, none of these side effects were observed, while clinical, laboratory and histopathological signs of ALF were evident. Conclusions: A reproducible model in pigs representing ALF can be established with the help of the standardized monitoring and treatment procedures presented.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.